Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-535-1456
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.32 million
Profitability
Miscellaneous
Employees83
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable
Arvinas (NASDAQ:ARVN) Frequently Asked Questions
What is Arvinas' stock symbol?
Arvinas trades on the NASDAQ under the ticker symbol "ARVN."
How were Arvinas' earnings last quarter?
Arvinas Inc (NASDAQ:ARVN) released its quarterly earnings data on Monday, November, 4th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.67. The company earned $30.05 million during the quarter, compared to the consensus estimate of $11.42 million. Arvinas had a negative return on equity of 31.57% and a negative net margin of 157.34%. View Arvinas' Earnings History.
When is Arvinas' next earnings date?
What price target have analysts set for ARVN?
10 brokers have issued twelve-month target prices for Arvinas' stock. Their forecasts range from $22.00 to $75.00. On average, they anticipate Arvinas' share price to reach $44.44 in the next twelve months. This suggests that the stock has a possible downside of 12.7%. View Analyst Price Targets for Arvinas.
What is the consensus analysts' recommendation for Arvinas?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas.
Has Arvinas been receiving favorable news coverage?
Media coverage about ARVN stock has been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arvinas earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Arvinas.
Are investors shorting Arvinas?
Arvinas saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 2,090,000 shares, an increase of 8.3% from the November 28th total of 1,930,000 shares. Based on an average daily trading volume, of 405,200 shares, the short-interest ratio is presently 5.2 days. Currently, 10.0% of the company's shares are short sold. View Arvinas' Current Options Chain.
Who are some of Arvinas' key competitors?
Some companies that are related to Arvinas include The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM) and FibroGen (FGEN).
What other stocks do shareholders of Arvinas own?
Who are Arvinas' key executives?
Arvinas' management team includes the folowing people:
- Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
- Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
- Dr. Ian Taylor, Chief Scientific Officer (Age 56)
- Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
- Dr. Andrew Crew, Chief Technology Officer (Age 54)
When did Arvinas IPO?
(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.
How do I buy shares of Arvinas?
Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arvinas' stock price today?
One share of ARVN stock can currently be purchased for approximately $50.91.
How big of a company is Arvinas?
Arvinas has a market capitalization of $1.72 billion and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. Arvinas employs 83 workers across the globe.View Additional Information About Arvinas.
What is Arvinas' official website?
How can I contact Arvinas?
Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]
MarketBeat Community Rating for Arvinas (NASDAQ ARVN)
MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
